View Older Stories View More Recent Stories

Apr 8, 2022 01:19PM Seagen (SGEN) Highlight Preclinical Data for Enfortumab Vedotin at AACR
Apr 8, 2022 01:19PM Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
Apr 7, 2022 08:00AM Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
Mar 16, 2022 06:30AM Seagen (SGEN) and Sanofi (SNY) Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
Mar 16, 2022 06:30AM Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
Mar 16, 2022 06:20AM Sanofi (SNY) and Seagen (SGEN) Collaborate to Develop and Commercialize Antibody-Drug Conjugates
Mar 16, 2022 06:18AM Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
Mar 16, 2022 06:18AM Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
Mar 1, 2022 08:00AM Seagen to Present at the Cowen 42nd Annual Health Care Conference
Feb 28, 2022 08:06AM Seagen (SGEN) and Astellas Announce CHMP Confirms Positive Opinion for PADCEV
Feb 28, 2022 08:00AM Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Feb 28, 2022 08:00AM Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Feb 24, 2022 10:01AM Genmab A/S (GMAB) and Seagen (SGEN) Report Data on Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma
Feb 24, 2022 10:00AM Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Feb 24, 2022 10:00AM Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Feb 24, 2022 10:00AM Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Feb 14, 2022 05:05PM Seagen (SGEN) and Astellas Report Initial Results of PADCEV in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
Feb 14, 2022 05:00PM Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
Feb 14, 2022 05:00PM Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
Feb 9, 2022 04:02PM Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 8, 2022 08:00AM Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Feb 3, 2022 08:03AM Seagen (SGEN) Announces ADCETRIS Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
Feb 3, 2022 08:00AM ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
Feb 1, 2022 08:00AM Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
Jan 20, 2022 08:00AM ShouTi Strengthens Board With Appointment of Daniel G. Welch as Chairman
Jan 18, 2022 05:01PM Seagen (SGEN) Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma
Jan 18, 2022 05:00PM Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Sympos
Jan 18, 2022 08:00AM Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
Dec 20, 2021 08:00AM Seagen to Present at the J.P. Morgan Healthcare Conference
Dec 17, 2021 06:40AM Astellas, Seagen (SGEN) Receive Positive CHMP Opinion for PADCEV in Locally Advanced or Metastatic Urothelial Cancer
Dec 17, 2021 06:40AM Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Dec 17, 2021 06:40AM Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Dec 13, 2021 04:58AM Seagen (SGEN) Reports Prelim Results from Phase 2 Clinical Trial of ADCETRIS
Dec 12, 2021 06:00PM Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymphoma
Dec 9, 2021 05:55AM Seagen (SGEN) Reports New Data from HER2CLIMB Trial Evaluating TUKYSA in Patients with HER2-Positive Breast Cancer with Brain Metastases
Dec 8, 2021 06:00PM Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases
Nov 19, 2021 09:33AM Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium
Nov 9, 2021 08:54AM Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting
Nov 4, 2021 09:31AM Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting
Oct 28, 2021 04:02PM Seagen Reports Third Quarter 2021 Financial Results
Oct 12, 2021 08:00AM Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Oct 12, 2021 08:00AM Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Oct 7, 2021 08:00AM Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
Sep 28, 2021 08:00AM Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
Sep 27, 2021 03:00AM Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
Sep 27, 2021 03:00AM Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
Sep 20, 2021 05:05PM Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval
Sep 20, 2021 05:03PM Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Sep 20, 2021 05:01PM Seagen (SGEN), Genmab Announce FDA Accelerated Approval for TIVDAK in Previously Treated Recurrent or Metastatic Cervical Cancer
Sep 20, 2021 05:00PM Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
View More Recent Stories View Older Stories